TW202110845A - 三環化合物 - Google Patents

三環化合物 Download PDF

Info

Publication number
TW202110845A
TW202110845A TW109118090A TW109118090A TW202110845A TW 202110845 A TW202110845 A TW 202110845A TW 109118090 A TW109118090 A TW 109118090A TW 109118090 A TW109118090 A TW 109118090A TW 202110845 A TW202110845 A TW 202110845A
Authority
TW
Taiwan
Prior art keywords
optionally substituted
group
alkyl
compound
unsubstituted
Prior art date
Application number
TW109118090A
Other languages
English (en)
Chinese (zh)
Inventor
桑德琳 范德維爾
Original Assignee
美商艾利格斯醫療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商艾利格斯醫療公司 filed Critical 美商艾利格斯醫療公司
Publication of TW202110845A publication Critical patent/TW202110845A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW109118090A 2019-05-30 2020-05-29 三環化合物 TW202110845A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962854597P 2019-05-30 2019-05-30
US62/854,597 2019-05-30

Publications (1)

Publication Number Publication Date
TW202110845A true TW202110845A (zh) 2021-03-16

Family

ID=73552666

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109118090A TW202110845A (zh) 2019-05-30 2020-05-29 三環化合物

Country Status (19)

Country Link
US (1) US11136321B2 (cg-RX-API-DMAC7.html)
EP (1) EP3976618A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022534501A (cg-RX-API-DMAC7.html)
KR (1) KR20220016177A (cg-RX-API-DMAC7.html)
CN (1) CN113906029A (cg-RX-API-DMAC7.html)
AU (1) AU2020282707B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021023967A2 (cg-RX-API-DMAC7.html)
CA (1) CA3138938A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021003139A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021017202A2 (cg-RX-API-DMAC7.html)
EA (1) EA202192760A1 (cg-RX-API-DMAC7.html)
IL (1) IL287813A (cg-RX-API-DMAC7.html)
MA (1) MA56058A (cg-RX-API-DMAC7.html)
MX (1) MX2021014458A (cg-RX-API-DMAC7.html)
PE (1) PE20220427A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021552953A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202113214QA (cg-RX-API-DMAC7.html)
TW (1) TW202110845A (cg-RX-API-DMAC7.html)
WO (1) WO2020243199A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220000874A1 (en) * 2019-05-30 2022-01-06 Aligos Therapeutics, Inc. Tricyclic compounds
US12703701B2 (en) * 2019-12-10 2026-08-11 Shanghai Hansoh Biomedical Co., Ltd. Pyrazole-containing polycyclic derivative inhibitor, preparation method therefor and application thereof
GB202103704D0 (en) * 2021-03-17 2021-04-28 Pathios Therapeutics Ltd Compounds
WO2022115384A1 (en) * 2020-11-24 2022-06-02 Aligos Therapeutics, Inc. Tricyclic compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0701273D0 (en) 2007-01-24 2007-02-28 Angeletti P Ist Richerche Bio New compounds
WO2008157273A1 (en) 2007-06-14 2008-12-24 Smithkline Beecham Corporation Chemical compounds
RU2016120763A (ru) * 2013-10-29 2017-12-05 Медивир Аб Ингибиторы респираторного синцитиального вируса
BR112018068177B1 (pt) 2016-03-09 2024-02-27 Emory University Composto, uso do composto e composição para eliminação do vírus da hepatite b com agentes antivirais
CN110066278B (zh) * 2017-06-01 2021-06-08 广东东阳光药业有限公司 稠合三环类化合物及其在药物中的应用

Also Published As

Publication number Publication date
BR112021023967A2 (pt) 2022-03-08
MA56058A (fr) 2022-04-06
CL2021003139A1 (es) 2022-09-23
EP3976618A1 (en) 2022-04-06
CN113906029A (zh) 2022-01-07
EP3976618A4 (en) 2023-01-04
JP2022534501A (ja) 2022-08-01
PH12021552953A1 (en) 2022-07-25
US20200407361A1 (en) 2020-12-31
CO2021017202A2 (es) 2022-01-17
MX2021014458A (es) 2022-01-06
WO2020243199A1 (en) 2020-12-03
EA202192760A1 (ru) 2022-03-05
PE20220427A1 (es) 2022-03-29
SG11202113214QA (en) 2021-12-30
CA3138938A1 (en) 2020-12-03
AU2020282707A1 (en) 2021-12-02
AU2020282707B2 (en) 2025-06-19
US11136321B2 (en) 2021-10-05
KR20220016177A (ko) 2022-02-08
IL287813A (en) 2022-01-01

Similar Documents

Publication Publication Date Title
US20230219926A1 (en) Substituted carboxamides as inhibitors of wdr5 protein-protein binding
ES2649144T3 (es) Compuestos heteroaromáticos y su uso como ligandos de dopamina D1
KR102030305B1 (ko) 키나제 억제제로서 유용한 인돌 카르복스아미드 화합물
EP3342771B1 (en) Heterocyclic amides as kinase inhibitors
CA2409743C (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
US11136321B2 (en) Tricyclic compounds
TWI819213B (zh) 雙環及三環化合物
KR102083818B1 (ko) 항 b형 간염 바이러스 피라졸-옥사졸리디논계 화합물
AU2021365812A1 (en) Bicyclic compounds
TW202237606A (zh) 三環化合物
CN113423712A (zh) 双环磺酰胺
WO2022266193A1 (en) Bicyclic compounds
EP4072670B1 (en) Quinazoline derivatives as lpa receptor 2 inhibitors
AU2021360496A1 (en) Bicyclic compounds
US20220000874A1 (en) Tricyclic compounds
AU2023353869A1 (en) Bicyclic compounds